Amicus Therapeutics is a publicly-held biopharmaceutical company located in New Jersey. The biotechnology company was established in 2002. It prides itself in facilitating revolutionary treatments for rare and distressing conditions. This includes conditions such as Fabry disease, genetic connective skin disorder, and Pompe disease among others. The company is passionate about facing the needs of people suffering from rare diseases.
Amicus Therapeutics develops innovative therapy options for various human genetic diseases. Some of the medical therapies are produced using enzyme replacement therapy technologies. The company maintains a bold vision for the future. It hopes to cover the full realm of rare diseases. For this reason, the company only works with the best available technologies. The company utilizes medical data to optimize the patient experience.
Besides patients, the company also develops strong relationships with caregivers and families of patients. The company supports patients and their communities (Yahoo). A wholesome approach to therapy produces better results. This focus on patient well-being has become the guiding principle of the corporate culture. Their decision-making structure envisions the patient as a member of their family.
Amicus Therapeutics is also passionate about compliance with industry frameworks and best practices. This guarantees high levels of safety and competence. The team at Amicus Therapeutics is led by the Chairman and CEO, John Crowley. He sets the vision and ignites its execution by enabling brilliant research, managing priorities and engaging the proper people to do the job.
John Crowley is a highly decorated veteran, biotechnology advocate, and author. He is a fellow at the Aspen Institute. He is also linked to the Make A Wish Foundation of America. John Crowley has over twenty years’ experience in the biotechnology industry.
Under his leadership, the company continues to deliver high-quality treatment options to persons living with rare conditions. It is constantly pushing innovation and creativity. The company is processing big ideas deeply and quickly. The disruptive products they provide are rewarding years of resilient belief.
Amicus Therapeutics continues to excel in scientific research and business leadership (https://www.dialdish.com/amicus-therapeutics-fabry-disease/). The biotechnology company builds strategic partnerships with various stakeholders. This enables them to maximize value in the company as the pillars of success. The company enjoys the support of a close family of teams with diverse skill sets.
More about Amicus Therapeutics on Facebook